



MTTI Receives Multimodality DPA Technology Patent

FOR IMMEDIATE RELEASE

West Chester, Pennsylvania, January 8, 2016--- Molecular Targeting Technologies, Inc., (MTTI) announced the issuance of U.S. Patent 9,211,349 entitled "Molecular probes for multimodality imaging of anionic membrane surface."

"DPA technology has the potential to target cell death as a means to intervene early in diseases and rapidly determine the effectiveness of treatments," said Professor Bradley D. Smith, Emil T Hoffman Professor of Chemistry and Biochemistry, University of Notre Dame and the inventor of original DPA technology. "Targeting cell death is broadly useful for treatment of numerous conditions, including cardiovascular diseases, cancer and inflammation. Previous DPA probes had only a fluorescence reporter group, but adding a second targeting modality greatly increases the utility of the probes and increases the potential for clinical translation."

Chris Pak, President and CEO of MTTI said, "We are pleased to receive the patent allowance of this technology to target cell death with a patent coverage until 2033. This technology can be used as an effective diagnostic to monitor cancer therapeutic treatment."

Molecular Targeting Technologies, Inc. (MTTI) is a privately held biotechnology company primarily focused on the acquisition and development of novel technologies for treatment and diagnosis of human diseases. MTTI has licensed and is developing two major technology platforms to provide: (i) novel small molecule drug conjugate (SMDC) cancer therapeutic, and (ii) in vivo imaging agents. Please visit our website: www.mtarget.com for more information.

Contacts:

Chris Pak, e-mail: cpak@mtarget.com; Tel: (610) 738-7938